ISTA Pharmaceuticals (ISTA) Bepreve Eye Drops Recommended For Approval By FDA Panel
More News related to ISTA
- ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
- After-Hours Movers 11/03: QLTY, PACR, BGCP, TESO Higher; STEC, TRLG, CLRT, CRL, MYGN Lower
- ISTA Pharmaceuticals (ISTA) Tops Q3 EPS by 3c; Guides In-line for FY Revenues
- Trading Radar for 11/03: UBS (UBS), Yamana Gold (AUY), Archer-Daniels (ADM), Royal Caribbean (RCL), Marathon (MRO) Report
- ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the American College of Clinical Pharmacy (ACCP) 2009 Annual Meeting
More News related to FDA
- Somaxon (SOMX) Volatile Into FDA Action Date
- Vivus (VVUS) Higher Ahead of Qnexa NDA
- Cardium (CXM) Subsidiary Files 510(k) with U.S. FDA for Excellagen Marketing Clearance
- Cardium (CXM) Files FDA 510(k) Application for Marketing Clearance of ExcellagenXL(TM) Topical Gel and Flowable Collagen
- Spectranetics (SPNC) Receives U.S. FDA OK for VisiSheath Dilator Sheath Device
ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) announced the Dermatologic and Ophthalmic Drugs Advisory Committee appointed by the FDA recommended the approval of Bepreve 1.5% as an eye drop treatment for ocular itching associated with allergic conjunctivitis.
The Committee voted unanimously 7 to 0 in favor of approving Bepreve after reviewing comprehensive safety and efficacy data from ISTA's clinical program.
NOTE: Shares of ISTA are currently halted, but are poised to open shortly.
Related Categories
FDAMomentum Movers
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
